Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study

Villanueva, Vicente; Serratosa, Joan; Guillamón, Edelmira; Garcés, Mercedes; Giráldez, Beatriz G.; Toledo, Manuel; Salas-Puig, Javier; González, Francisco Sánchez-Montes; Flores, Juan; Rodríguez-Uranga, J.; Castillo, Agustín Diez; Mauri, J.A.; Camacho, J.L.; López-Gomáriz, Elena; Giner, P.; Torres, Nicolás; Palau, Juan; Molins, A

doi:10.1016/j.eplepsyres.2014.04.014

Cited by 64 publications

(99 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results might be explained by the fact that EPOS population seemed to be less refractory in comparison to our study, as suggested by a shorter mean time since epilepsy diagnosis (12.3±12.1 years in EPOS19 vs 18.5±14.8 years in this study). On the other hand, the responder rate attained in this study is significantly higher than the ones reported in the 1‐year and 2‐year retrospective studies16, 18 at 6 months (57.9% and 25.7%, respectively). Two main reasons might be responsible for these differences.…”

Section: Discussioncontrasting

confidence: 82%

“…vs mean of 18.5±14.8 years in this study) and the number of baseline AEDs used (patients used up to five and six AEDs at baseline in Correia et al 16. and Villanueva et al.,18 respectively, vs only one baseline AED in this study). Higher RR was observed when ESL was combined with CBZ (85.7%), VPA (73.3%), and LEV (72.7%), demonstrating that ESL was well retained in all combinations.…”

Section: Discussionmentioning

confidence: 55%

“…First, the responder rate observed in the ESLADOBA study may be overestimated, as it only considered patients who completed the study (responder rate was calculated not considering the patients who were dropped‐out from the study, n=14). Second, the patients included in the two retrospective studies were more refractory than the ESLADOBA population, as reflected by longer times since epilepsy diagnosis (median of 19.0 years in Villanueva et al 18. vs median of 16.0 years in this study; mean of 26.8±13.1 years in Correia et al 16.…”

Section: Discussionmentioning

confidence: 72%

“…Additionally, 9.6% of the patients discontinued ESL due to AEs, which is lower than the percentages reported in EPOS (11.4%),17 in Villanueva et al. (13.4%),18 and in Correia et al. (21.1%) studies,16 and in the integrated analysis of pooled data from the phase III clinical trials (approximately 14.0%) 9.…”

Section: Discussionmentioning

confidence: 74%

“…This study showed RR of 73.0% at the Vfinal. At 6 months, higher RR was found in a similar non‐interventional prospective study (EPOS)17 (82.2%), in a 1‐year retrospective study18 (80.1%), and in a 2‐year retrospective study16 (82.9%). The lower RR obtained in this study may be due to an underestimation, as a worst scenario was used by classifying those patients that did not perform the final assessment as failures.…”

Section: Discussionmentioning

confidence: 89%

See 4 more Smart Citations

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study

Chaves¹,

Breia

Pimentel

et al. 2017

Acta Neurol Scand

View full text Add to dashboard Cite

ObjectiveTo assess seizure control and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy to one baseline antiepileptic drug (AED), in adults with partial‐onset seizures (POS) with or without secondary generalization.MethodsMulticenter, non‐interventional, prospective cohort study conducted between March 2012 and September 2014 at 12 neurology departments in Portugal. Adults with POS not controlled with one AED who had initiated ESL as adjunctive treatment were enrolled. Retention rate was defined at the final visit (Vfinal) 6‐9 months of follow‐up. Proportion of responders, seizure‐free, changes in seizure frequency were evaluated using patients' diaries. Clinical Global Impression of Change (CGI‐C) and Clinical Global Impression of Severity (CGI‐S) were assessed by the neurologist.ResultsFifty‐two patients (48.1% male) were included with mean age 41.5±13.3 years. Mean epilepsy duration was 18.5±14.8 years; mean seizure frequency in the four previous weeks to baseline was 7.5±12.7. At Vfinal, retention rate was 73.0%; responder rate and seizure‐free rates were 71.1% and 39.5%, respectively. The median relative reduction in seizure frequency between baseline and Vfinal was 82.2%. A reduction in epilepsy severity (CGI‐S) was observed in 42.1%. According to CGI‐C, 73.6% patients had their epilepsy “much improved” or “very much improved”. Twelve patients (23.1%) had at least one adverse event (AE), two (3.9%) had one serious AE, and five (9.6%) discontinued due to AE.ConclusionsEslicarbazepine acetate showed good retention rates, elicited a significant reduction in seizure frequency, and was well tolerated when used in the clinical practice.

show abstract

Section: Discussioncontrasting

confidence: 82%

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 89%

See 3 more Smart Citations

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study

Chaves¹,

Breia

Pimentel

et al. 2017

Acta Neurol Scand

View full text Add to dashboard Cite

show abstract

Transition from oxcarbazepine to eslicarbazepine acetate: A single center study

2017

View full text Add to dashboard Cite

ObjectivesThere is limited clinical evidence for comparison between oxcarbazepine (OXC) and eslicarbazepine acetate (ESL) in terms of tolerability, or how to execute the change from OXC to ESL. We report the process of transitioning patients with focal epilepsy from previous OXC treatment to ESL due to tolerability problems. The rationale for change from OXC is reported, and the outcome with respective to this rationale is analyzed in terms of tolerability and efficacy.Materials and MethodsThe subjects were transitioned overnight from OXC to ESL in a hospital inpatient setting. An evaluation of the effects of the transition was made after 1 and 3 months. All adverse events (AEs) were recorded following the transition period. Subjects were classified by outcome in terms of AEs.ResultsTwenty‐three subjects were transitioned from OXC to ESL. Fifteen patients OXC‐related AEs reduced significantly after transition. Particularly, most of (93%) the AEs presented in the morning resolved after transition to ESL. No patient had an increase in seizure frequency following the transition. The incidence of ESL‐related AEs was 39% at 1 month and 13% at 3 month follow‐up; however, all patients continued ESL throughout the study period.ConclusionsThis study demonstrates that patients suffering from OXC‐related AEs improve in terms of tolerability after a switch to ESL with maintaining seizure control. This improvement is more pronounced if the OXC‐related AEs are most evident following morning dosing of OXC. Transition can be safely executed in an outpatient setting.

show abstract

Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia

Sánchez-Larsen

Sopelana

Díaz-Maroto

et al. 2018

European Journal of Pain

View full text Add to dashboard Cite

show abstract

Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study

Cited by 64 publications

References 26 publications

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study

Transition from oxcarbazepine to eslicarbazepine acetate: A single center study

Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia

Contact Info

Product

Resources

About